Gynecologic Oncology | Specialty

Trastuzumab Duocarmazine Shows Superiority Over Physician’s Choice for HER2+ Breast Cancer

June 8th 2021

The antibody-drug conjugate vic-trastuzumab duocarmazine was found to significantly improve progression-free survival over physician’s choice of treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer, meeting the primary end point of the phase 3 TULIP trial.

Pertuzumab/Trastuzumab Combo Elicits Clinical Activity in ERBB2/ERBB3+ Uterine Cancer

June 7th 2021

The combination of pertuzumab and trastuzumab elicited a 37% disease control in patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer.

Updates in Genitourinary, Gynecologic Cancers From ASCO 2021: Drs Nick Vogelzang and Erin Crane

June 7th 2021

OncLive sits down with Nicholas J. Vogelzang, MD, and Erin K. Crane, MD, MPH to discuss the biggest abstracts in genitourinary cancers and gynecologic cancers, respectively, at the 2021 ASCO Annual Meeting.

Prolonged Treatment With Bevacizumab Does Not Yield Further Survival Benefit in Ovarian Cancer

June 7th 2021

Although prolonged treatment with bevacizumab for up to 30 months is feasible with consistent safety data for patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer, the regimen did not improve survival over the standard 15 month treatment regimen.

Niraparib Individualized Starting Dose Tolerable in Platinum-Sensitive Recurrent Ovarian Cancer

June 5th 2021

Niraparib, when delivered at an individualized starting dose, was found to be well tolerated in patients with platinum-sensitive recurrent ovarian cancer.

The Future of Endometrial Cancer Treatment

June 4th 2021

Experts give insight on what they are looking forward to in the endometrial cancer space.

A Look at Surgical Innovations in EC

June 4th 2021

Nicoletta Colombo, MD, PhD, reviews surgical advancements in endometrial cancer.

Novel Targets of Interest in EC

June 4th 2021

Experts in endometrial cancer comment on novel targets of interest that are currently being investigated.

Progression-Free Survival Improves With Niraparib Maintenance Treatment in Subset of Ovarian Cancer

June 4th 2021

Maintenance therapy with niraparib significantly improved progression-free survival in patients with BRCA mutated ovarian cancer, according to results from three phase 3 trials.

Insight on Ongoing Trials in EC

June 4th 2021

Key opinion leaders take a look at the evolving treatment landscape in endometrial cancer, discussing ongoing trials in the space.